Instrument Inactif

Communiqués Vitae Pharmaceuticals Inc

Actions

US92847N1037

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

14/09/16	NASDAQ Comp : Wall Street termine dans le rouge, Apple monte encore	RE
14/09/16	Allergan : rachète un spécialiste des maladies auto-immunes	RE

Communiqués

17/10/16	Vitae Pharmaceuticals : Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae	PR
15/09/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
15/09/16	Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Vitae Pharmaceuticals, Inc. to Allergan plc for $21.00 Per Share	BU
15/09/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
14/09/16	VITAE PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
14/09/16	Vitae Pharmaceuticals : Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions	PR
01/09/16	Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference	GL
11/08/16	Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference	GL
10/08/16	Vitae Pharmaceuticals Appoints Scott Applebaum as General Counsel and Corporate Secretary	GL
03/08/16	Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results	GL
01/08/16	Vitae Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 3, 2016	GL
27/07/16	Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors	GL
14/06/16	Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference	GL
06/06/16	Vitae Pharmaceuticals : Announces Appointment of Carole Sable, M.D., as Chief Medical Officer	PU
06/06/16	Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer	GL
10/05/16	Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results	GL
09/05/16	Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016	GL
03/05/16	Vitae Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 10, 2016	GL
30/03/16	Vitae Pharmaceuticals Closes Public Offering of Common Stock	GL
24/03/16	Vitae Pharmaceuticals Prices Public Offering of Common Stock	GL
23/03/16	Vitae Pharmaceuticals Proposes Public Offering of Common Stock	GL
16/03/16	Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis	GL
03/03/16	Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results	GL
25/02/16	Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016	GL
29/12/15	Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis	GL